Coppola A, Cimino E, Conca P, De Simone C, Tufano A, Tarantino G, Cerbone A M, Minno G
Regional Reference Centre for Coagulation Disorders, Department of Clinical and Experimental Medicine, 'Federico II' University, Naples, Italy.
Haemophilia. 2006 Jan;12(1):90-4. doi: 10.1111/j.1365-2516.2006.01184.x.
Prophylaxis with von Willebrand factor (VWF)-containing concentrates is considered to be a potential approach for patients with von Willebrand disease (VWD) and severe bleeding tendency. We report the case of a 57-year-old man with type 3 VWD and a history of recurrent melaena. Bleeding frequency and severity had progressively increased and the patient showed chronic anaemia and persistent haemoglobin in the stools. Endoscopic examinations revealed multiple vascular mucosal abnormalities (MVA) of the stomach and large bowel. Photocoagulation of some actively bleeding lesions and octreotide did not significantly affect his clinical conditions: six red cell transfusions and >400 000 IU of intermediate-purity factor VIII (FVIII) concentrate (Haemate P) on-demand were needed during 2002. Prophylaxis with Haemate P 40 IU kg(-1) (102 IU kg(-1) VWF:RCo) thrice weekly was associated with improvement of his mean haemoglobin levels, cessation of clear-cut melaena and red cell transfusions and reduction of total Haemate P requirements (-20% over 2003-04). Prophylaxis with Haemate P is still ongoing without any adverse event over a 30-month period. Clinical course and pharmacokinetic evaluations led to administer Haemate P each 72-96 h. Possible vascular complications were excluded by a careful clinical follow up, as the patient suffered from arterial hypertension and diabetes mellitus; thrombophilic abnormalities were previously excluded and no signs of abnormal coagulation activation or FVIII:C levels >150% were detected thereafter. Long-term prophylaxis with Haemate P has been shown to be safe, effective (also in terms of quality of life) and cost saving in this patient with severe gastrointestinal bleeding due to MVA and VWD.
对于患有血管性血友病(VWD)且有严重出血倾向的患者,使用含血管性血友病因子(VWF)的浓缩物进行预防被认为是一种潜在的方法。我们报告了一例57岁的3型VWD男性患者,有反复黑便病史。出血频率和严重程度逐渐增加,患者出现慢性贫血且粪便中持续有血红蛋白。内镜检查发现胃和大肠有多处血管黏膜异常(MVA)。对一些活动性出血病变进行光凝和使用奥曲肽对其临床状况没有显著影响:2002年期间,患者按需输注了6次红细胞以及超过40万国际单位的中纯度因子VIII(FVIII)浓缩物(海莫莱士)。每周三次预防性使用40 IU/kg(102 IU/kg VWF:RCo)的海莫莱士与患者平均血红蛋白水平的改善、明显黑便和红细胞输注的停止以及海莫莱士总需求量的减少(2003 - 2004年期间减少20%)相关。在30个月的时间里,仍在继续使用海莫莱士进行预防,未出现任何不良事件。临床病程和药代动力学评估导致每72 - 96小时给予一次海莫莱士。由于患者患有动脉高血压和糖尿病,通过仔细的临床随访排除了可能的血管并发症;之前已排除血栓形成异常,此后未检测到异常凝血激活迹象或FVIII:C水平>150%。对于因MVA和VWD导致严重胃肠道出血的该患者,长期使用海莫莱士进行预防已被证明是安全、有效的(在生活质量方面也是如此)且节省成本。